Healio

Infliximab bests cyclophosphamide as first-line treatment of severe Behçet’s syndrome

Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...
Healio

Adalimumab slashes Behçet’s uveitis relapse rate significantly more than cyclosporine

Please provide your email address to receive an email when new articles are posted on . Adalimumab plus corticosteroids significantly outperformed cyclosporine plus corticosteroids to delay Behçet’s ...
MarketWatch

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

The MarketWatch News Department was not involved in the creation of this content. -- Study results support advancing SGX945 in this difficult-to-treat orphan disease -- Results suggest potential ...
Medscape

British Societies Develop First 'Living' Behçet Guidelines

LIVERPOOL, ENGLAND — The British Society for Rheumatology (BSR) and the British Association of Dermatologists (BAD) have joined forces for the first time to develop the first British guidelines for ...
The New England Journal of Medicine

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study

Methods We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Behçet’s syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast ...
Seeking Alpha

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...
MedPage Today

EULAR Updates Its Guidance on Managing Behcet's Syndrome

Behçet's syndrome is a form of autoimmune vasculitis marked by widespread and sometimes life-threatening cardiovascular complications, as well as skin, nervous system, and gastrointestinal lesions.
Seeking Alpha

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (SNGX) (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing ...
sciencex

EULAR updates Behçet’s syndrome care, urging earlier monoclonal TNF inhibitors

The EULAR recommendations for the management of Behçet's syndrome were first published in 2008, and updated in 2018. Since that time, new evidence has become available, including trials of biologic ...
Nature

Behçet's Disease and Associated Conditions

Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.
Morningstar

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

PRINCETON, N.J., Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...